

Special Issue

COVID-19 Medicines in Pharmacogenomics

Message from the Guest Editors

Pharmacogenomics has begun to move to the center stage of COVID-19 drug design and development, including repurposed drugs and different vaccine platforms that are being used for COVID-19. Predefined drug (i.e., authorized for emergency use) safety and efficacy can be detected more effectively through pharmacogenomics during and after clinical trials.

This Special Issue invites potential manuscripts that cover topics including pharmacogenomics, biomarkers, drug repurposing, drug–target interactions, drug–gene interactions, and advances in artificial intelligence in pharmacogenomics related to COVID-19 and coronavirus-mediated disease.

Guest Editors

Dr. Satyavani Kaliyamurthi


Centre for Research in Molecular Modeling (CERMM), Concordia University, Montreal, QC H4B1R6, Canada

Dr. Gurudeeban Selvaraj

Centre for Research in Molecular Modeling (CERMM), Concordia University, Montreal, QC H4B1R6, Canada

Deadline for manuscript submissions

closed (20 February 2024)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/135266

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).